<DOC>
	<DOCNO>NCT02903797</DOCNO>
	<brief_summary>The purpose study determine serum irisin hormone level relation endometrial hyperplasia</brief_summary>
	<brief_title>Irisin Hormone Levels Endometrial Hyperplasia</brief_title>
	<detailed_description>The study consist two group . The first group form patient diagnosed endometrial hyperplasia histopathologically , control healthy woman admit clinic annual examination without complain symptom . Patients 35-50 age range group include study . The histopathologic diagnosis patient establish Kayseri Education Research Hospital Pathology clinic . Demographic parameter age , menopausal status , body mass index ( BMI ) , body weight know familial cancer story register . Pregnancy , liver function disorder , cardiovascular disease , metabolic disease , diabetes , chronic kidney disease , central nerve system disease , immunosuppressive drug use , another know malignancy excessive exercise among one month exclusion criterion patient . 3 cc peripheral venous blood sample take patient ' diagnose endometrial hyperplasia course evaluation biopsy result controls examination . Blood sample centrifuge 3200 rpm speed 10 minute , store -80 ' C analysis . Blood sample evaluate day four mount store first blood sample . Serum Irisin level evaluate enzyme- link immunosorbent assay kit ( Catalog number : K4761-100 Biovision USA ) Kayseri Research Education Hospital Biochemical Clinics .</detailed_description>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Endometrial Hyperplasia</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>3550 year age Ä°n endometrial hyperplasia group ; patient diagnose endometrial hyperplasia histopathologically Pregnancy Liver function disorder Cardiovascular disease Metabolic disease Diabetes Chronic kidney disease Central nerve system disease Immunosuppressive drug use Another know malignancy Excessive exercise among one month</criteria>
	<gender>Female</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Endometrial hyperplasia</keyword>
	<keyword>Irisin</keyword>
	<keyword>fibronectin type III domain contain 5</keyword>
	<keyword>FNDC5 ( fibronectin type III domain containing )</keyword>
</DOC>